MSD is a company that is ‘serious about science.’ In 2024, its global research and development investment reached $17.9 ...

The U.S. Food and Drug Administration’s (or FDA) approval for Keytruda on October 2, 2015, to treat patients suffering with advanced non-small cell lung cancer (or NSCLC) is considered to be a major ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent cliff ...